Incyte Says It's No Longer A One-Drug Story
Incyte Corp. (NASDAQ: INCY ) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opzelura and its hematology and oncology products. The biopharmaceutical company reported adjusted earni